User: Guest  Login
Title:

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

Document type:
Journal Article; Clinical Trial; Clinical Trial, Phase I; Article
Author(s):
Meyer, RG; Britten, CM; Siepmann, U; Petzold, B; Sagban, TA; Lehr, HA; Weigle, B; Schmitz, M; Mateo, L; Schmidt, B; Bernhard, H; Jakob, T; Hein, R; Schuler, G; Schuler-Thurner, B; Wagner, SN; Drexler, I; Sutter, G; Arndtz, N; Chaplin, P; Metz, J; Enk, A; Huber, C; Wölfel, T
Abstract:
A significant percentage of patients with stage II melanomas suffer a relapse after surgery and therefore need the development of adjuvant therapies. In the study reported here, safety and immunological response were analyzed after vaccination in an adjuvant setting with recombinant modified vaccinia virus Ankara carrying the cDNA for human tyrosinase (MVA-hTyr). A total of 20 patients were included and vaccinated three times at 4-week intervals with 5x10(8) IU of MVA-hTyr each time. The respons...     »
Journal title abbreviation:
Cancer Immunol Immunother
Year:
2005
Journal volume:
54
Journal issue:
5
Pages contribution:
453-67
Language:
eng
Fulltext / DOI:
doi:10.1007/s00262-004-0616-7
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/15627214
Print-ISSN:
0340-7004
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Virologie ; Klinik und Poliklinik für Dermatologie und Allergologie
 BibTeX